Cells are infused intravenously to reach the damaged nerves.
We treat diabetic, chemotherapy-induced, idiopathic small-fiber, and post-surgical peripheral neuropathy. A typical protocol delivers 50 million mesenchymal stem cells by intravenous infusion, with 100 million cells for established symptomatic disease. Gabapentin, pregabalin, and duloxetine reduce pain signals; the cellular protocol targets the neuroinflammation and microvascular damage that injure the nerve fibers themselves.
The infusion takes 60 to 90 minutes and requires no anesthesia. Where a specific injured nerve can be identified, an image-guided perineural injection at the lesion site is added. A physician prescribes the protocol after a full neurological workup.
We treat four forms of peripheral neuropathy.
The forms of peripheral neuropathy we treat, and the protocol a case typically starts from. The final prescription is always the physician's, after your neurological workup is reviewed.
Diabetic Peripheral
The most prevalent form, affecting roughly half of adults with long-standing diabetes. Driven by chronic hyperglycemia, oxidative stress, and microvascular damage to the small vessels that supply peripheral nerves. The best-studied indication for MSC therapy in neuropathy.
UC‑MSC 50M IV · 100M high‑doseChemotherapy-Induced
A dose-limiting toxicity of platinum agents, taxanes, vinca alkaloids, and bortezomib that often persists long after treatment ends. For patients who have completed cytotoxic therapy, are stable on oncology surveillance, and have their oncologist's sign-off.
UC‑MSC 50–100M IV · exosome adjunctIdiopathic Small-Fiber
A sensory-predominant pattern — often burning pain in the feet with normal nerve conduction studies. Considered after a thorough metabolic and autoimmune workup has ruled out treatable causes.
UC‑MSC 50M IV · Muse cell optionPost-Surgical & Post-Traumatic
Localized nerve damage following surgery, injury, or compression. Where a specific injured nerve can be identified, image-guided perineural injection at the lesion site can be added to the systemic protocol.
Local UC‑MSC + PRP · IV systemicDoses run from 50 to 100 million cells.
Neuropathy is distributed along long peripheral nerves, so delivery is systemic by design — intravenous as the primary route, scaled to the severity of disease. Every dose is expanded from Wharton's jelly umbilical-cord tissue.
50M
cells intravenously — the anti-inflammatory dose for less-severe presentations, delivered in a 60–90 minute infusion.
100M
cells for established symptomatic neuropathy — the high-dose systemic protocol, with targeted perineural injection where a specific lesion can be reached.
ISO‑certified
GMP laboratory. Each dose is released only after sterility, identity, and viability verification.
What happens along the nerve.
Tap a step to follow the cells to the damaged fibers.
What recovery looks like.
Nerve repair takes months. A typical timeline, tailored by your physician to your case.
Day 0
Same-day infusion
60–90 minutes in a private suite. Mild fatigue or transient flushing in the first 24 hours is the typical pattern. Most patients fly home the next day.
Weeks 1–6
First early signals
Mild reduction in pain or burning intensity is the most common early signal. Some patients report sleep improvement first.
Months 3–6
Primary endpoint
Structured re-measurement of pain scales, neurological exam, and — where indicated — repeat nerve conduction.
Month 12
Durability check
Responders are typically still improving or holding a better baseline. Re-treatment may be considered for partial responders who tolerated the first protocol well.
The evidence, briefly.
Three anchor findings from the peer-reviewed literature.
~50%
of adults with long-standing diabetes develop peripheral neuropathy. Standard drugs manage the symptoms; the underlying nerve damage persists.
Feldman EL, et al. Nat Rev Dis Primers, 2019.
Meta-analysis
Pooled controlled trials of stem cell therapy in diabetic neuropathy report improvements in pain scores and nerve conduction velocity versus standard care.
Hu Y, et al. Stem Cell Res Ther, 2021.
Safety
Updated systematic review: intravascular MSC administration continues to appear safe, with adverse events typically mild and transient.
Thompson M, et al. EClinicalMedicine, 2020.
The honest framing: the evidence base for cellular therapy in peripheral neuropathy is earlier-stage than for joint osteoarthritis. The signals from diabetic-neuropathy trials are encouraging and consistent in direction, but long-term comparative data, optimal dosing, and durability of effect are still being established — and for chemotherapy-induced neuropathy the published evidence is earlier still, resting on preclinical work and small series rather than large randomized trials. The realistic goal is symptom reduction, improved function, and reduced reliance on symptomatic medications; no cure is guaranteed. End-stage sensory loss with complete denervation is unlikely to be reversed, and this therapy is not a substitute for glycemic control, oncology surveillance, or neurology-led immunomodulation. Not FDA-approved for these uses; provided in México under COFEPRIS after individual physician review of your history, medications, and nerve-conduction workup.
